secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036123
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carmell sells Axolotl Biologix subsidiary for shares and $8M note cancellation
------------------------------------------------------------------------------

- Returns 3,845,337 common shares and 4,243 preferred shares to original sellers; cancels $8 million note payable.
- Exits tissue graft space; sharpens focus on skincare product launches beginning March 2024 through Summer 2024.
- Expects $4 million annualized drop in cash burn net of revenue from AxoBio's January 2024 run rate.
- Reduces total debt by $15.6 million ($7.6M sub debt + $8M note); adds $7M tangible equity; cuts EPS dilution 29%.
- Post-closing: 19.25 million common shares outstanding; retained focus on aesthetics pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017024036123/0000950170-24-036123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017024036123/ctcx-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer